Skip to content

Oligasis LLC Becomes Kodiak Sciences Inc.

  • Company emerges with a potentially disruptive retinal pipeline

Kodiak Sciences Inc., a biopharmaceutical company founded in 2009 as Oligasis LLC, announced the launch of its new corporate identity. The company’s new identity reflects the maturation of the company’s product pipeline and highlights the company’s commitment to building a durable, independent ophthalmology franchise for the benefit of patients globally. For more information please visit the company’s website at localhos:8080.

About Kodiak

Kodiak is designing and developing novel therapies for the treatment of retinal disease.


Additional Information and Disclaimer

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Kodiak Sciences Inc., although Kodiak Sciences Inc. can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Kodiak Sciences Inc. disclaims any intention or obligation to update the statements contained in this news release.

Media Inquiries